AstraZeneva and The Medicines Company to co-promote Brilinta in USA

AstraZeneca and The Medicines Company have announced a global collaboration for their acute ischaemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca�s oral antiplatelet medicine Brilinta (ticagrelor).Under the terms of the co-promotion agreement, The Medicines Company sales force will begin supporting Brilinta in May 2012. This will complement the AstraZeneca sales team�s promotion of Brilinta to US hospital customers and practitioners whose patients with Acute Coronary Syndrome (ACS) may benefit from this therapy.Under the terms of the global collaboration, a joint development committee and a joint commercialisation committee have been established to prepare and deliver global development and commercialisation plans related to AstraZeneca�s Brilinta and The Medicines Company�s Angiomax (bivalirudin) for injection and cangrelor, which is in development as an acute intravenous antiplatelet agent. Implementation of these plans is subject to further agreements between both parties.